Publications by authors named "Karla M Opheim"
Reprint of: The impact of alpha-1-adrenergic receptor antagonists on the progression of Parkinson disease.
J Am Pharm Assoc (2003)
October 2024
Background: Alpha-1-adrenergic receptor antagonists (AARAs) are used in the treatment of benign prostatic hypertrophy. Some AARAs, such as terazosin, stimulate glycolysis and increase cellular adenosine triphosphate levels through activation of phosphoglycerate kinase 1 (PGK1), which has been suggested to be of therapeutic benefit in patients with Parkinson disease (PD).
Objective: This study aimed to determine whether exposure to PGK1-activating AARAs was associated with slower PD progression.
The impact of alpha-1-adrenergic receptor antagonists on the progression of Parkinson disease.
J Am Pharm Assoc (2003)
March 2024
Background: Alpha-1-adrenergic receptor antagonists (AARAs) are used in the treatment of benign prostatic hypertrophy. Some AARAs, such as terazosin, stimulate glycolysis and increase cellular adenosine triphosphate levels through activation of phosphoglycerate kinase 1 (PGK1), which has been suggested to be of therapeutic benefit in patients with Parkinson disease (PD).
Objective: This study aimed to determine whether exposure to PGK1-activating AARAs was associated with slower PD progression.